Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), OnKure ...

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Telix Pharmaceuticals (TLPPF – Research Report), Mer...

Analysts’ Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Mereo Biopharma Group Plc (MREO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Solventum Corporation (SOLV – Research Report) and Praxis Precisi...

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...

Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Dexcom (DXCM)

Praxis Precision Medicines ( ($PRAX) ) just unveiled an update. On January 6, 2026, Praxis Precision Medicines entered into an underwriting agreeme...

Praxis Precision Medicines Announces Major Underwritten Equity Offering

In a report released yesterday, Kambiz Yazdi from BTIG maintained a Buy rating on Praxis Precision Medicines, with a price target of $843.00. The c...

Current Quarter	$-2.97	Next Quarter	$-2.84
Current Year	$-12.98	Next Year	$-13.06
QoQ Growth	+4.4%	YoY Growth	-0.6%
3Y EPS CAGR	+44.3%	Target Price	$525.93
Consensus	Buy	Upside	+70.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PRAX	$309.11	-1.56%	587.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PRAX	$309.11	-1.6%	587.61K
3
4
5
6

PRAX

PRAX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Praxis Precision Medicines Inc. Data in Excel

Get Praxis Precision Medicines Inc. Data in Excel